

SUPPLEMENTARY DATA

In vitro and *in silico* evaluation of new oxadiazole derivatives of pyrrolo[3,4-d]pyridazinone as promising cyclooxygenase inhibitors

Krzysztof Peregrym¹, Łukasz Szczukowski¹, Benita Wiatrak², Katarzyna Potyrak², Żaneta Czyżnikowska³ and Piotr Świątek¹

¹ Department of Medicinal Chemistry, Faculty of Pharmacy, Wrocław Medical University, Borowska 211, 50-556 Wrocław, Poland; krzysztof.peregrym@student.umed.wroc.pl (K.P.), lukasz.szczukowski@umed.wroc.pl (Ł.S.), piotr.swiatek@umed.wroc.pl (P.Ś.)

² Department of Pharmacology, Faculty of Medicine, Wrocław Medical University, Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland; benita.wiatrak@umed.wroc.pl (B.W.), katarzyna.potyrak@student.umed.wroc.pl (K.P.)






³ Department of Inorganic Chemistry, Wrocław Medical University, Borowska 211, 50-556 Wrocław, Poland; zaneta.czyznikowska@umed.wroc.pl (Ż.C.)


* Correspondence: piotr.swiatek@umed.wroc.pl ; Tel.: +48 71 784 03 91

Table of contents


Table S1. Structures of new compounds.....	2
Table S2. NMR spectra of new compounds	5
Table S3. IR spectra of new compounds	17
Table S4. Mass spectra of new compounds	23
Table S5. The 2D intermolecular interactions of investigated compounds in the active site of COX.....	29
Table S6. Binding mode of investigated compounds to COX-1.....	41
Table S7. Binding mode of investigated compounds to COX-2.....	43

Table S1. Structures of new compounds



2a

2b

3a

3b

4a




4b




5a




5b




6a



6b





7a




7b

Table S2. NMR spectra of new compounds







2b




2b




3a




3a




3b




3b




4a




4a




4b




4b




5a




5a




5b




5b




6a




6a




6b




6b




7a



7a







7b




7b


Table S3. IR spectra of new compounds









4a




4b




5a




5b




6a



6b




7a




7b


Table S4. Mass spectra of new compounds




2a




2b




3a




3b




4a




4b




5a




5b




6a



6b



7a



7b

Table S5. The 2D intermolecular interactions of investigated compounds in the active site of COX

Figure S1. The intermolecular interactions of **2a** in the active centre of a) COX-1 b) COX-2




Figure S2. The intermolecular interactions of **2b** in the active centre of a) COX-1 b) COX-2




Figure S3. The intermolecular interactions of **3a** in the active centre of a) COX-1 b) COX-2




Figure S4. The intermolecular interactions of **3b** in the active centre of a) COX-1 b) COX-2




Figure S5. The intermolecular interactions of **4a** in the active centre of a) COX-1 b) COX-2




Figure S6. The intermolecular interactions of **4b** in the active centre of a) COX-1 b) COX-2




Figure S7. The intermolecular interactions of **5a** in the active centre of a) COX-1 b) COX-2




Figure S8. The intermolecular interactions of **5b** in the active centre of a) COX-1 b) COX-2




Figure S9. The intermolecular interactions of **6a** in the active centre of a) COX-1 b) COX-2




Figure S10. The intermolecular interactions of **6b** in the active centre of a) COX-1 b) COX-2




Figure S11. The intermolecular interactions of **7a** in the active centre of a) COX-1 b) COX-2




Figure S12. The intermolecular interactions of **7b** in the active centre of a) COX-1 b) COX-2






Table S6. Binding mode of investigated compounds with COX-1

Binding mode of compounds **a)** 2a, 2b, 3a, 3b, 4a, 4b; **b)** 5a, 5b, 6a, 6b, 7a, 7b; to the COX-1 obtained from molecular docking (by colour are marked amino acid residues responsible for meloxicam binding)

<p>a</p> <p style="text-align: center;">Compounds 2a 2b 3a 3b 4a 4b</p>  <p style="text-align: center;">pyrrolo[3,4-d]pyridazin-4-one scaffold 1,3,4-oxadiazole-2-thione moiety phenylpiperazine pharmacophore</p>			
<p>2a</p> <p>R¹ (-C₆H₆) R² (-CH₃, -CH₃)</p>	<p>Leu117 Ile345 Val349 Leu352 Leu359 Met522 Gly526 Ala527 Ser530 Ile531 Leu534 Leu535</p>	<p>Leu93 Met113 Tyr355 Leu357 Leu359</p>	<p>Arg83 Pro86 Ile89 Val116 Val119 Arg120 Leu123 Glu524</p>
<p>2b</p> <p>R¹ (-C₄H₉) R² (-CH₃, -CH₃)</p>	<p>Arg83 Pro86 Ser87 Ile89 His90 Leu93 Val116 Val119 Arg120 His513 Glu520 Ile523 Glu524</p>	<p>Leu93 Arg120 Tyr355 Leu359 Leu531</p>	<p>Tyr348 Val349 Leu352 Leu384 Tyr385 Trp387 Met522 Gly526 Ala527 Ser530</p>
<p>3a</p> <p>R¹ (-C₆H₆) R² (-F, -F)</p>	<p>Leu117 Val349 Leu352 Leu357 Leu359 Trp387 Phe518 Met522 Gly526 Ala527 Ser530 Leu531</p>	<p>Ile89 Leu93 Val116 Arg120 Tyr355 Leu359</p>	<p>Pro86 Ser87 Ile89 His90 His513 Glu520 Ile523 Glu524</p>
<p>3b</p> <p>R¹ (-C₄H₉) R² (-F, -F)</p>	<p>Leu93 Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu352 Leu359 Tyr355 Gly526 Ala527</p>	<p>Val344 Tyr348 Leu352 Trp387 Ser530 Leu531 Ser353 Leu534</p>	<p>Phe205 Phe209 Gly227 Val228 Ile337 Asn375 Phe381 Tyr385 Ser530 Gly533</p>
<p>4a</p> <p>R¹ (-C₆H₆) R² (-Cl, -Cl)</p>	<p>Leu93 Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu357 Leu359 Ala527 Leu531 Leu534</p>	<p>Phe205 Val344 Tyr348 Leu352 Ser353 Leu354 Tyr355 Tyr385 Trp387 Gly526 Ser530</p>	<p>Phe205 Phe209 Val228 Asn375 Phe381 Tyr385 Gly533 Leu534</p>
<p>4b</p> <p>R¹ (-C₄H₉) R² (-Cl, -Cl)</p>	<p>Val349 Leu352 Ser353 Phe381 Leu384 Tyr385 Trp387 Phe518 Met522 Ile523 Gly526 Ala527 Ser530 Leu351</p>	<p>Met113 Leu117 Val349 Leu531 Leu534 Leu535</p>	<p>Leu93 Met113 Val116 Arg120 Ile345 Tyr355 Leu357 Leu359</p>
<p>Meloxicam</p>	<p>Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu352 Ser353 Tyr355 Leu359 Tyr385 Trp387 Phe518 Met522 Ile523 Gly526 Ala527 Ser530 Leu531 Leu534 Leu535</p>		

b


Compounds 5a 5b 6a 6b 7a 7b



5a R ¹ (-C ₆ H ₆) R ² (-CH ₃ , -CH ₃)	Met113 Leu117 Ile345 Val349 Leu352 Ile523 Gly526 Ala527 Ser530 Leu531 Leu534 Leu535	Arg120 Ser353 Leu359 Ala527	Arg83 Pro86 Ile89 Leu93 Met113 Val116 Val119 Arg120 Tyr355 Leu357 Glu524
5b R ¹ (-C ₄ H ₉) R ² (-CH ₃ , -CH ₃)	Val349 Leu352 Ser353 Leu384 Phe381 Tyr385 Trp387 Phe518 Met522 Ile523 Gly526 Ser530	Val349 Tyr355 Leu359 Ala527 Leu531	Pro86 Ile89 His90 Leu93 Val116 leu117 Arg120 Leu357 Glu524
6a R ¹ (-C ₆ H ₆) R ² (-F, -F)	Ile345 Val344 Val349 Leu352 Ile523 Ala527 Ser530 Leu531 Leu534	Leu93 Met113 Val116 Leu117 Arg120 Tyr355 Leu357 Gly526 Leu535	Arg83 Ile89 Leu123 Gly471 Glu524 Pro528
6b R ¹ (-C ₄ H ₉) R ² (-F, -F)	Met113 Phe205 Val344 Val349 Leu352 Ser353 Tyr385 Trp378 Phe518 Ile523 Ala527 Ser530 Leu531 Ser535	Arg120 Ile345 Tyr355 Val349 Leu534 Leu359	Ile89 Leu93 Trp100 Leu112 Val116 Tyr355 Leu357
7a R ¹ (-C ₆ H ₆) R ² (-Cl, -Cl)	Ile345 Val349 Leu359 Met522 Ile523 Gly526 Ala527 Ser530 Leu531 Leu534	Met113 Val116 Ser353 Tyr355 Ala527	Pro86 Ile89 His90 Leu112 Val116 Leu117 Arg120 Leu357 Glu524 Leu535
7b R ¹ (-C ₄ H ₉) R ² (-Cl, -Cl)	Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu359 Leu531 Leu534 Leu535	Leu117 Arg120 Val349 Tyr355 Ala527 Ser530	His90 Gln192 Leu352 Ser353 His513 Ser516 Ile517 Phe518 Ile523
Meloxicam	Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu352 Ser353 Tyr355 Leu359 Tyr385 Trp387 Phe518 Met522 Ile523 Gly526 Ala527 Ser530 Leu531 Leu534 Leu535		


Table S7. Binding mode of investigated compounds with COX-2

Binding mode of compounds **a)** 2a, 2b, 3a, 3b, 4a, 4b; **b)** 5a, 5b, 6a, 6b, 7a, 7b; to the COX-2 obtained from molecular docking (by colour are marked amino acid residues responsible for meloxicam binding)

<p>a</p> <p style="text-align: center;">Compounds 2a 2b 3a 3b 4a 4b</p>  <p style="text-align: center;">pyrrolo[3,4-d]pyridazin-4-one scaffold 1,3,4-oxadiazole-2-thione moiety phenylpiperazine pharmacophore</p>			
<p>2a</p> <p>R¹ (-C₆H₆) R² (-CH₃, -CH₃)</p>	<p>Val349 Leu352 Ser353 Leu384 Trp387 Met522 Val523 Ala527 Ser530 Ser535</p>	<p>Ile345 Leu531 Leu534 Met535</p>	<p>Leu93 Met113 Val116 Leu117 Arg120 Tyr355 Phe357 Leu359 Phe381 Gly527</p>
<p>2b</p> <p>R¹ (-C₄H₉) R² (-CH₃, -CH₃)</p>	<p>His90 Tyr348 Val349 Leu352 Ser353 Phe381 Tyr385 Trp387 Met522 Val523 Gly526 Ala527 Ser530 Leu531</p>	<p>Leu93 Val116 Arg120 Tyr355</p>	<p>Met113 Leu117 Ile345 Leu359 Ser530 Leu531</p>
<p>3a</p> <p>R¹ (-C₆H₆) R² (-F, -F)</p>	<p>Leu93 Met113 Val116 Leu117 Arg120 Tyr355 Ala527 Leu531 Leu534 Met535 Leu359</p>	<p>Ser353 Phe518 Val523 Gly526 Ser530</p>	<p>Phe205 Thr206 Phe209 Val344 Tyr348 Val349 Leu352 Phe381 Tyr385 Trp387 Met522 Ser530</p>
<p>3b</p> <p>R¹ (-C₄H₉) R² (-F, -F)</p>	<p>His90 Val349 Ser352 Ser353 Phe381 Leu384 Tyr385 Trp387 Phe518 Met522 Val523 Gly526 Ala527 Met535</p>	<p>Leu93 Val116 Arg120 Tyr355</p>	<p>Met113 Val116 Leu117 Arg120 Ile349 Leu359 Ser530 Leu531 Leu534</p>
<p>4a</p> <p>R¹ (-C₆H₆) R² (-Cl, -Cl)</p>	<p>Leu93 Met113 Val116 Leu117 Arg120 Ile345 Tyr355 Leu359 Ala527 Leu531 Leu534 Met535</p>	<p>Val349 Leu352 Gly526 Ser530 Leu531</p>	<p>Phe205 Phe209 Gly227 Val228 Val344 Tyr348 Asn375 Ile377 Phe381 Tyr385 Trp387 Phe529 Ser530 Gly533</p>
<p>4b</p> <p>R¹ (-C₄H₉) R² (-Cl, -Cl)</p>	<p>Tyr348 Val349 Leu352 Tyr385 Trp387 Phe381 Ile517 Phe518 Met522 Val532 Gly526 Ala527 Ser530 Ser353</p>	<p>Val344 Val349 Ser530 Leu531 Ser353 Leu534</p>	<p>Met113 Leu117 Arg120 Ile345 Tyr355 Leu359 Leu531 Met535</p>
<p>Meloxicam</p>	<p>Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu352 Ser353 Tyr355 Leu359 Tyr385 Trp387 Phe518 Met522 Val523 Ala527 Ser530 Leu531 Leu534 Met535</p>		

b

Compounds 5a 5b 6a 6b 7a 7b



5a R ¹ (-C ₆ H ₆) R ² (-CH ₃ , -CH ₃)	His90 Leu352 Ser353 Phe381 Leu384 Tyr385 Trp387 Phe518 Met522 Val523 Gly526 Ala527 Ser530	Arg120 Tyr355 Ala527 Ser530	Met113 Val116 Leu117 Arg120 Val344 Ile345 Leu534 Met535
5b R ¹ (-C ₄ H ₉) R ² (-CH ₃ , -CH ₃)	Tyr348 Val349 Leu352 Phe381 Tyr385 Trp387 Val523 Phe518 Met522 Gly526 Ala527 Ser530 Ser535	Tyr355 Ala527 Ser530	Leu93 Met113 Val116 Leu117 Arg120 Ile345 Phe357 Leu359 Leu531
6a R ¹ (-C ₆ H ₆) R ² (-F, -F)	Leu352 Ser353 Phe381 Tyr385 Trp387 Met522 Val523 Gly526 Phe518 Ala527	His90 Val349 Ser530 Leu531 Leu534	Leu93 Met113 Val116 Leu117 Arg120 Ile345 Tyr355 Leu359 Met535
6b R ¹ (-C ₄ H ₉) R ² (-F, -F)	Tyr348 Val349 Leu352 Phe381 Leu384 Tyr385 Trp387 Phe518 Met522 Val523 Gly526 Ala527 Leu534	Arg120 Val349 Tyr355 Ser530 Leu531 Ser353	Val89 Leu93 Met113 Val116 Leu117 Ser119 Arg120 Phe357 Leu359
7a R ¹ (-C ₆ H ₆) R ² (-Cl, -Cl)	Phe381 Leu384 Tyr385 Trp387 Leu352 Phe518 Met522 Val523 Gly526 Ser530	His90 Val349 Tyr355 Ala527 Ser530 Ser353 Leu534	Val89 Leu93 Met113 Val116 Leu117 Arg120 Ile345 Phe357 Leu359 Leu531
7b R ¹ (-C ₄ H ₉) R ² (-Cl, -Cl)	Val349 Leu352 Ser353 Tyr355 Phe381 Leu384 Tyr385 Trp387 Phe518 Met522 Val523 Gly526 Leu534	Met113 Ile345 Leu349 Leu359 Ala527 Ser530 Leu531	Val89 Leu93 Tyr115 Val116 Leu117 Ser119 Arg120 Ile345
Meloxicam	Met113 Val116 Leu117 Arg120 Ile345 Val349 Leu352 Ser353 Tyr355 Leu359 Tyr385 Trp387 Phe518 Met522 Val523 Gly526 Ala527 Ser530 Leu531 Leu534 Leu535		